Renowned African Swine Fever Researcher, Douglas Gladue, PhD, joins Seek Labs as Vice President of Veterinary Pharmaceutical Development

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based pharmaceutical technology, is pleased to announce the appointment of Dr. Douglas Gladue, PhD as the new Vice President of Veterinary Pharmaceutical Development. Dr. Gladue, an internationally recognized expert in African Swine Fever (ASF) research and development, brings decades of knowledge and experience in ASF vaccine research and development to Seek Labs where he will lead research and development efforts in CRISPR-based veterinary pharmaceutical projects.

Dr. Gladue is an internationally recognized virologist and ASF expert and leader in vaccine development and swine genomics. He has previously led and developed vaccines from concept to commercialization for foreign animal diseases at the Plum Island Animal Disease Center for the Agricultural Research Service (ARS) in the U.S. Department of Agriculture (USDA). In his role with the USDA, he led research, invented, and commercialized the first and second live-attenuated vaccines for ASF, significantly contributing to the global management of this critical agricultural issue. Dr. Gladue is also one of the only ARS recipients in history to receive the prestigious Arthur S. Flemming award for his ASF vaccine accomplishments.

In his new role with Seek Labs, Dr. Gladue will spearhead veterinary pharmaceutical research utilizing the company’s CRISPR technology. His expertise in vaccine development and disease trials is instrumental in enhancing Seek Labs’ research capabilities and development efforts for veterinary applications.

"We are excited to welcome Dr. Douglas Gladue to our growing pharmaceutical team," said Jared Bauer, CEO of Seek Labs. “Dr. Gladue’s unparalleled expertise in African Swine Fever and his visionary approach to research and vaccine development align with our strategic goals to develop solutions using our CRISPR technologies. We are confident his leadership will propel our pharmaceutical research to veterinary applications.”

Dr. Gladue earned a B.S. in Microbiology from the University of Rhode Island and went on to earn a PhD in Molecular Genetics and Microbiology from Stony Brook University. He is an Executive Board Member and Scientific Director for the Global African Swine Fever Research Alliance (GARA). Additionally, he serves as an Editorial Board Member for several scientific journals, including the Journal of Virology and of Viruses.

“I am excited to join Seek Labs and lead veterinary pharmaceutical development,” said Dr. Gladue. “Seek Labs is trailblazing new solutions for complex viral diseases like African Swine Fever with their CRISPR technology approach. Seek Labs’ unique approach shows great promise to develop a targeted and effective solution for ASF as well as other agricultural diseases.”

For more information about Seek Labs and the development of CRISPR-based pharmaceutical technology, please visit www.seeklabs.com.

About Seek Labs

Seek Labs is a company united by a vision to advance scientific discovery and universal solutions. Seek Labs strives to innovate healthcare solutions that bridge gaps between patients, providers, and treatments. Seek Labs is united by the passion of our founders and their shared beliefs that healthcare solutions should empower individuals and serve their specific needs. Today, Seek Labs is developing new solutions for point-of-care diagnostics and CRISPR-based pharmaceutical technologies that have the potential to revolutionize the detection and treatment of diseases.

Seek Labs is headquartered in Salt Lake City, Utah. Seek Labs is a proud member of the BioHive, a collective representing the life science and healthcare innovation ecosystem in Utah. BioHive is dedicated to all the ways our work can positively impact the lives of our community, our teams, and patients.